Management of hepatitis C in patients with chronic kidney disease

被引：8
作者：
Mohammad A. B. Al-Freah
Zeino Zeino
Michael A. Heneghan
机构：
[1] Institute of Liver Studies, King's College Hospital, NHS Foundation Trust, London SE5 9RS, Denmark Hill
来源：
Current Gastroenterology Reports | 2012年 / 14卷 / 1期
关键词：
Hemodialysis; Hepatitis C; Kidney; Renal; Transplantation;
D O I：
10.1007/s11894-011-0238-0
中图分类号：
学科分类号：
摘要：
Chronic kidney disease represents a global health problem. Chronic hepatitis C virus (HCV) infection is prevalent in patients with end stage renal disease (ESRD) on hemodialysis (HD) and in renal transplant recipients with significant impact on morbidity and mortality. Furthermore, HCV can cause various forms of glomerulopathy with the predominant type being cryglobulinemia associated membranoproliferative glomerulonephritis. Liver enzymes are traditionally used as markers of liver injury; however, there is wide variation in aminotransferase levels in patients with ESRD. Therefore, diagnosis of chronic hepatitis C (CHC) in patients with ESRD is based on HCV antibody testing and further confirmation with polymerase chain reaction testing. Current standard therapy for CHC is composed of pegylated interferon and ribavirin. However, this combination is challenging in patients with ESRD due to its tolerability. We describe in this review relevant issues in epidemiology, diagnosis and management of CHC in ESRD, HD and renal transplant recipients. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：78 / 86
页数：8
相关论文
共 93 条
[1]  
Poynard T., Yuen M.-F., Ratziu V., Lung Lai C., Viral hepatitis C, Lancet, 362, 9401, pp. 2095-2100, (2003)
[2]  
Finelli L., Miller J.T., Tokars J.I., Alter M.J., Arduino M.J., National surveillance of dialysis-associated diseases in the United States, 2002, Seminars in Dialysis, 18, 1, pp. 52-61, (2005)
[3]  
Di Napoli A., Pezzotti P., Di Lallo D., Petrosillo N., Trivelloni C., Di Giulio S., Epidemiology of Hepatitis C Virus Among Long-Term Dialysis Patients: A 9-Year Study in an Italian Region, American Journal of Kidney Diseases, 48, 4, pp. 629-637, (2006)
[4]  
Fabrizi F., Martin P., Ponticelli C., Hepatitis C virus infection and renal transplantation, American Journal of Kidney Diseases, 38, 5, pp. 919-934, (2001)
[5]  
Furusyo N., Hayashi J., Kanamoto-Tanaka Y., Ariyama I., Etoh Y., Shigematsu M., Kashiwagi S., Liver damage in hemodialysis patients with hepatitis C virus viremia: A prospective 10-year study, Digestive Diseases and Sciences, 45, 11, pp. 2221-2228, (2000)
[6]  
Wreghitt T.G., Blood borne virus infections in dialysis units - A review, Reviews in Medical Virology, 9, 2, pp. 101-109, (1999)
[7]  
Amiri Z.M., Shakib A.J., Toorchi M., Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran, East Mediterr Health J, 11, 3, pp. 372-376, (2005)
[8]  
Fissell R.B., Bragg-Gresham J.L., Woods J.D., Jadoul M., Gillespie B., Hedderwick S.A., Rayner H.C., Greenwood R.N., Akiba T., Young E.W., Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS, Kidney International, 65, 6, pp. 2335-2342, (2004)
[9]  
Sypsa V., Psichogiou M., Katsoulidou A., Skoutelis G., Moutafis S., Hadjiconstantinou V., Kakavas J., Kalapothaki V., Boletis J., Hatzakis A., Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients, American Journal of Kidney Diseases, 45, 2, pp. 334-343, (2005)
[10]  
Kalantar-Zadeh K., Kilpatrick R.D., McAllister C.J., Miller L.G., Daar E.S., Gjertson D.W., Kopple J.D., Greenland S., Hepatitis C virus and death risk in hemodialysis patients, Journal of the American Society of Nephrology, 18, 5, pp. 1584-1593, (2007)
12345678910